Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) has developed a breakthrough blood test detecting chronic fatigue syndrome with 96% accuracy. The test uses its EpiSwitch platform and could eventually be adapted for long Covid. Watch more
IP Group PLC (LSE:IPO) could earn significant royalties after Pfizer announced it's acquiring obesity drug developer Metsera for $7.3 billion. CEO Greg Smith says IP Group is the licensor of the fundamental technology behind Metsera’s lead compounds. Watch more
Solvonis Therapeutics PLC (LSE:SVNS) raised £1.25 million to accelerate CNS drug development, including addiction and psychiatry programmes. With an advanced clinical programme for severe alcohol use disorder, targeting the EU and UK markets.CEO Anthony Tennyson says phase 2b trials are also planned for alcohol use disorder in the US. Watch more
IXICO PLC (LSE:IXI, OTC:PHYOF) saw above-guidance revenue in 2025, driven by new contracts and Alzheimer’s-focused projects. CEO Bram Goorden highlighted progress in blood-based biomarker diagnostics and US operational scale-up. Watch more
Light Science Technologies Holdings PLC (AIM:LST) announced an extended agreement with Gavita and Agrolux, which now runs until December 2026. CEO Simon Deacon says this will enable LST to support international projects with its turnkey lighting, sensing and environmental control solutions. Watch more
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.